MicroRNA signature in patients with hepatocellular carcinoma associated with type 2 diabetes

doi:10.3748/wjg.v25.i42.6322

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 25, Issue 42

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9292)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-6) series, Tables (1-10) series.

Item

Count

PDF

578

WORD

295

HTML

5203

Figures (1-6)

318

Tables (1-10)

273

Sum=6667

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1038

Download

1587

Sum=2625

Nov 14, 2019 (publication date) through Dec 1, 2024

Times Cited of This Article

Times Cited (21)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Control Study

World J Gastroenterol. Nov 14, 2019; 25(42): 6322-6341
Published online Nov 14, 2019. doi: 10.3748/wjg.v25.i42.6322

Table 7 Significant microRNAs expression as average fold change = (2^-ΔΔCT) in the liver cirrhosis group vs the hepatocellular carcinoma group

MiRNA name	HCC	LC	Fold change	Log₂ fold change	P value
hsa-miR-23b-3p	2.44	0.78	0.32	-1.64	0.001^a
hsa-miR-34a	1.88	0.16	0.09	-3.47	0.001^a
hsa-miR-122-5p	0.34	0.98	0.12	2.87	0.001^a
hsa-miR-198	0.88	0.29	0.33	-4.64	0.001^a
hsa-miR-199a-3p	1.18	0.31	0.26	-1.94	0.001^a
hsa-miR-221	1.13	3.31	2.92	1.55	0.001^a

^aP < 0.005 with ± 1.5 log₂ fold expression change. HCC: Hepatocellular carcinoma; LC: Liver cirrhosis; miRNA: MicroRNA.

Citation: Elemeery MN, Mohamed MA, Madkour MA, Shamseya MM, Issa NM, Badr AN, Ghareeb DA, Pan CH. MicroRNA signature in patients with hepatocellular carcinoma associated with type 2 diabetes. World J Gastroenterol 2019; 25(42): 6322-6341
URL: https://www.wjgnet.com/1007-9327/full/v25/i42/6322.htm
DOI: https://dx.doi.org/10.3748/wjg.v25.i42.6322